Neuphoria Therapeutics Inc.

For the period ended Jun 30, 2026. Filed Sep 18, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2026 · Filed Sep 18, 2026

NEUP$2.76-0.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Neuphoria Therapeutics Inc.
Date: September 18, 2026	By:	/s/ Spyridon Papapetropoulos, M.D.
	Name:	Spyridon Papapetropoulos
	Title:	Interim Chief Executive Officer and Director
Date: September 18, 2026	By:	/s/ Timothy Cunningham
	Name:	Timothy Cunningham
	Title:	Chief Financial Officer and Principal Financial Officer
Date: September 18, 2026	By;	/s/ Miles Davies
	Name:	Miles Davies
	Title:	Director
Date: September 18, 2026	By:	/s/ Alan Fisher
	Name:	Alan Fisher
	Title:	Director
Date: September 18, 2026	By:	/s/ Jane Ryan
	Name:	Jane Ryan
	Title:	Director
Date: September 18, 2026	By:	/s/ David Wilson
	Name:	David Wilson
	Title:	Director

Index to Consolidated Financial Statements

Report of Independent Registered Public Accounting Firm (PCAOB ID: 392)	F-2
Consolidated Balance Sheets	F-3
Consolidated Statements of Operations and Other Comprehensive Income (Loss)	F-4
Consolidated Statements of Changes in Shareholders' Equity	F-5
Consolidated Statements of Cash Flows	F-6
Notes to Consolidated Financial Statements	F-7

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.